Short Interest in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Increases By 119.5%

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 391,100 shares, a growth of 119.5% from the December 15th total of 178,188 shares. Approximately 2.0% of the shares of the company are sold short. Based on an average trading volume of 597,371 shares, the short-interest ratio is currently 0.7 days. Based on an average trading volume of 597,371 shares, the short-interest ratio is currently 0.7 days. Approximately 2.0% of the shares of the company are sold short.

Analysts Set New Price Targets

ARTV has been the subject of several analyst reports. HC Wainwright upped their price target on Artiva Biotherapeutics from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. Wedbush upped their price objective on shares of Artiva Biotherapeutics from $18.00 to $23.00 and gave the stock an “outperform” rating in a research report on Friday, October 17th. Jefferies Financial Group upgraded shares of Artiva Biotherapeutics to a “strong-buy” rating in a research note on Tuesday, November 18th. Needham & Company LLC reiterated a “buy” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Friday, October 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV opened at $4.78 on Thursday. Artiva Biotherapeutics has a one year low of $1.47 and a one year high of $7.50. The firm has a market capitalization of $117.35 million, a P/E ratio of -1.85 and a beta of 2.92. The company’s fifty day moving average is $3.94 and its two-hundred day moving average is $3.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, sell-side analysts forecast that Artiva Biotherapeutics will post -4.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Artiva Biotherapeutics news, CEO Fred Aslan sold 25,500 shares of the stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $6.00, for a total transaction of $153,000.00. Following the completion of the sale, the chief executive officer directly owned 356,721 shares of the company’s stock, valued at approximately $2,140,326. This trade represents a 6.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders sold 35,062 shares of company stock worth $193,670. 21.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several institutional investors have recently modified their holdings of ARTV. Citadel Advisors LLC grew its holdings in shares of Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after acquiring an additional 644,658 shares during the period. BNP Paribas Financial Markets boosted its position in Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after purchasing an additional 117,733 shares in the last quarter. Marshall Wace LLP acquired a new stake in Artiva Biotherapeutics in the second quarter valued at $79,000. Jane Street Group LLC purchased a new position in shares of Artiva Biotherapeutics in the second quarter valued at $67,000. Finally, Landscape Capital Management L.L.C. acquired a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth $112,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.